SEC Form 4 · accession 0001615774-17-004563

Tonix Pharmaceuticals Holding Corp. · TNXP

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Aug 16, 2017

Accepted (ET)

Aug 18, 2017 · 3:40 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001430306

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock, $0.001 par value	Aug 16, 2017	P	5,000	$2.99	A	35,000	I	By IRA account
Common Stock, $0.001 par value	Aug 17, 2017	P	15,000	$3.0045	A	50,000	I	By IRA account
Common Stock, $0.001 par value	holding	—	—		—	13,300	I	By 401(k) plan
Common Stock, $0.001 par value	holding	—	—		—	11,166	D
Common Stock, $0.001 par value	holding	—	—		—	3,100	I	By spouse
Common Stock, $0.001 par value^F1	holding	—	—		—	3	I	By Leder Laboratories, Inc.
Common Stock, $0.001 par value^F1	holding	—	—		—	2,917	I	By Starling Pharmaceuticals, Inc.
Common Stock, $0.001 par value^F1	holding	—	—		—	18,463	I	By Lederman & Co., LLC
Common Stock, $0.001 par value^F1	holding	—	—		—	3,246	I	By L&L Technologies, LLC
Common Stock, $0.001 par value^F1	holding	—	—		—	5,898	I	By Targent Pharmaceuticals, LLC

No Table II lines on this filing.